Another class I and II HDAC inhibitor, Tacedinaline, demonstrates potential in downregulating the BIRC5 gene, which is frequently overexpressed in resistant breast cancer cells, and in suppressing apoptotic protein expression [121]. Here, HDAC9 is linked to breast carcinoma.